What's in Antonios Likourezos's pipeline?

Antonios Likourezos has 4 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Antonios Likourezos's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/antonios-likourezos.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Antonios Likourezos — Portfolio Competitive Intelligence Brief

Antonios Likourezos pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase
Ketamine via BAN	Ketamine via BAN	marketed
Nebutlized Ketamine	Nebutlized Ketamine	marketed
aspirin and ketamine	aspirin and ketamine	marketed
Standard-vaginal misoprostol	Standard-vaginal misoprostol	marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Antonios Likourezos:

Cite this brief

Drug Landscape (2026). Antonios Likourezos — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/antonios-likourezos. Accessed 2026-05-16.